

# Material Safety Data Sheet

Effective Date:

Due Date:

## Section 1 : Chemical Product Company Identification

Product Name	Pitavastatin 3-Oxo Sodium
CAT No.	KMP138013
CAS No.	NA
Identified uses	Pharmaceutical Reference Standard
Details of the Supplier Company	K. M. PHARMA SOLUTION PRIVATE LIMITED Unit No.101, Shivam Industrial park, Sarkhej-bavala NH=8A, At-Moraiya, Changodar, Ahmedabad (Gujarat), India-382213
Telephone	+91 9898822121

## Section 2 : Chemical Information

Chemical Name	Sodium (S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-5-hydroxy-3-oxohept-6-enoate
CAS No.	NA
Molecular Weight	418.4 : 23.0
Molecular Formula	C25H21FNO4 : Na

## Section 3 : Hazards Identification

### Emergency Overview:

Appearance	NA
Target Organs	NA

### Potential Health Effects:

Eye	NIL
Skin	NIL
Ingestion	NIL
Inhalation	NIL
Chronic	NIL



## Section 4 : First Aid Measures

Eye	Wash with plenty of water
Skin	Wash with plenty of water
Ingestion	Medical assistance for gastric lavage.
Inhalation	Remove to fresh air, artificial respiration or oxygen if necessary.
Notes to Physician	Pitavastatin 3-Oxo Sodium can be washed with plenty of water in case of any exposure

## Section 5 : Firefighting Measures

Extinguishing Media	Carbon dioxide, dry chemical powder, foam, water.
Unusual Fire and Explosion Hazards	None indicated

## Section 6 : Accidental Release Measures

Personal Precautions	Wear self-contained breathing apparatus, avoid dust formation.
Spills/Leaks	Wash with plenty of water, provide adequate ventilation.

## Section 7 : Handlings and Storage

Handling	Wear surgical gloves
Storage	~Storage

## Section 8 : Exposure Controls, Personal Protection

Respiratory Protection	Self-contained breathing apparatus
Exposure Limits	NA
Eye Protection	Wear safety goggles
Other Protective Equipment	Protective clothing
Skin	Full sleeves apron
Clothing	Cotton

## Section 9 : Physical and Chemical Properties

Appearance	NA
Odor	NA
Melting Point	NA



pH	NA
Vapor Pressure	NA
Vapor Density	NA
Evaporation Rate	NA
Viscosity	NA
Boiling Point	NA
Decomposition Temp	NA
Auto ignition Temp.	NA
Flash Point	NA
NFPA Rating	NA
<b>Explosion Limits</b>	
Lower	NA
Upper	NA
Solubility	NA
Specific Gravity/Density	NA

## Section 10 : Stability and Reactivity

Chemical Stability	~ChemicalStability
Conditions to avoid	Direct contract to skin
Incompatibilities with other Materials	Keep away
Hazardous Decomposition Products	NIL
Hazardous Polymerization	NIL

## Section 11 : Toxicological Information

CAS	NA
LD50/LC50	>10,000 mg/kg Remarks: Behavioral:Somnolence (general depressed activity)
Carcinogenicity	NIL
Epidemiology	NIL
Teratogenicity	NIL
Reproductive Effects	NIL
Neurotoxicity	NIL



Mutagenicity	NIL
Other Studies	NA

### Section 12 : Ecological Information

Data not available

### Section 13 : Disposal Consideration

RCRA P-Series	Can be incinerated
RCRA U-Series	NA

### Section 14 : Transport Consideration

<b>UN-Number</b>
ADR/RID:    IMDG:    IATA:
<b>UN proper shipping name</b>
ADR/RID: Not dangerous goods IMDG: Not dangerous goods IATA: Not dangerous goods
<b>Transport hazard class(es)</b>
ADR/RID:    IMDG:    IATA:
<b>Packaging Group</b>
ADR/RID:    IMDG:    IATA:
<b>Environmental hazards</b>
ADR/RID: No IMDG Marine pollutant: No IATA: No
<b>Special precautions for users</b>
<b>Further information</b>

### Section 15 : Regulatory Information

TSCA	Attached the letter
Health & Safety Reporting List	No data available
Chemical Test Rules	Chemical analysis report is attached



## Section 16 : Additional Information

This product is not bioactive, non-radioactive. It is for R&D use only. Not for drug, household or other uses.

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge. It does not represent any guarantee of the product.

K.M. Pharma Solution Private Limited

